# Long-Term Clinical and Echocardiographic Follow-Up of the Freestyle Stentless Aortic Bioprosthesis – the Tel Medical Center Experience

Schwartz Lorin, MD<sup>1\*</sup>, Topilsky Yan, MD<sup>1\*</sup>, Uretzky Gideon, MD<sup>2</sup>, Nesher Nahum, MD<sup>2</sup>, Ben-Gal Yanai<sup>2</sup>, MD ,Biner Simon, MD<sup>1</sup>, Keren Gad, MD<sup>1</sup>, Kramer Amir, MD<sup>2</sup>

<sup>1</sup>Division of Cardiovascular Diseases Tel Aviv Medical Center

<sup>2</sup>Division of Cardiovascular Surgery, Tel Aviv Medical Center

**DISCLOSURE - NONE** 

# Background

 Stentless aortic bioprostheses were designed to provide improved hemodynamic performance and potentially better survival.

### • Aims:

 Outcomes of patients after aortic valve replacement with the Freestyle stentless bioprosthesis in the Tel Aviv Medical Center followed for ≤15 years

# Methods and results

• Between 1997 and 2011, 268 patients underwent primary aortic valve replacement with a Freestyle bioprosthesis

Variables	All
Age (years)	71.0±9.3
Sex Male	58%
Renal failure (Creatinine>1.7%)	11%
Diabetes Mellitus (%)	27%
LV ejection fraction (<35%;%)	6%
Logistic EuroScore‡	11±10.2
Charlson Score‡	4.2±1.5
Ejection fraction (%)	51.9±12.1
Peak trans-aortic gradient (mmHg)	75.0±29
Mean trans-aortic gradient (mmHg)	43.4±17
Aortic valve area (cm <sup>2</sup> )	$0.78\pm0.3$
Systolic pulmonary pressure (mmHg)	37.1±14.7
≥Moderate Mitral regurgitation (%)	10

- 211 (79%) subcoronary position.
- Peak and mean trans-aortic gradient
  22.8±9.6mmHg and 12.1±5.4mmHg in 3
  months follow up.
- In-hospital mortality 4.1% (n=11), but differed significantly between the first 100 patients operated before 2006 (8 patients [8.0%]) to the last 168 patients operated after January 2006 (3 patients [1.8%]; p=0.01).

- 5-year survival rates were 85±2.5%.
- 5-year survival was markedly improved in patients operated after January 2006 compared to those operated on at the early years of the experience (92.3±2.3% vs. 76.0±4.4%; p=0.0009).
- All 21 octogenarians operated after January 2006 survived surgery, with excellent 5-year survival (85.1±7.9%).
- Six patients required reoperation during follow-up: for structural valve deterioration in five and endocarditis in one.

## • Discussion:

- AVR with the Freestyle bioprosthesis provides good long-term hemodynamic and clinical outcomes, even in octogenarians.
- Valve calcification is the major (and rare) mode of valve deterioration leading to reoperation in these patients.

# Strengths:

the acquisition of wide clinical, as well as
 echocardiographic data with up to 15 years of follow up
 after surgery is a significant strength of our study.